drugset
drugset / Trial / NCT01962636

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636 ↗

Terminated 200 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).

Timeline

Start
2016-12
Primary completion
2026-05-14
Completion
2026-05-14

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Background Cyclosporine Peptide 2.5 mg/kg Oral
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background Influenza Virus Vaccine Vaccine — Other
Background Mycophenolate Mofetil Small molecule 15 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule 3 g Intravenous

Indications

Burkitt lymphoma acute myeloid leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myeloid leukemia diffuse large B-cell lymphoma follicular lymphoma lymphoblastic lymphoma lymphoplasmacytic lymphoma mantle cell lymphoma marginal zone lymphoma myelodysplastic syndrome myelofibrosis plasma cell leukemia plasma cell myeloma prolymphocytic leukemia